GRAL
Diagnostics & Research · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when GRAIL, Inc. publishes a filing, an earnings call transcript or a press release.
Get GRAL alertsAaron Freidin is recorded as CFO at GRAIL, Inc. (GRAL). The newest filing on record that lists Aaron Freidin as CFO at GRAIL, Inc. (GRAL) is dated April 28, 2026. GRAIL, Inc. reported in an 8-K filed June 24, 2024 that Aaron Freidin was appointed Chief Financial Officer, effective June 21, 2024. The proxy statement of GRAIL, Inc. reports total compensation of $3,131,535 for Aaron Freidin in fiscal 2025, including a base salary of $560,000. Disclosed compensation is on record for 3 fiscal years. Aaron Freidin has spoken on 8 earnings calls and 2 other investor events across 1 company, most recently for GRAIL, Inc. on August 11, 2026. GRAIL, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at GRAIL, Inc. includes Dr. Joshua Ofman (CEO), Joshua Ofman (CEO and Board Member), Robert P. Ragusa (CEO and Board Member) and 7 others.
“on June 21, 2024, the Board made the following officer appointments, effective immediately:”
“We had a revenue growth of about 30% and volume growth of about 42%, over 117,000 tests now in the first half.”
“Reported earnings, 50% volume growth, $40 million in revenue, which is 37% growth year over year. Really excited with where we ended up. Continue to see strong growth and momentum in our provider channels, also in our digital health channels.”
“I'm pleased to present our results for the first quarter. First quarter results were strong with revenue of $40.8 million, up $8.9 million or 28% as compared to the first quarter of 2025.”
“I'm pleased to present our results for the fourth quarter and the full year of 2025. Fourth quarter results were strong with revenue of $43.6 million, up $5.3 million or 14% compared to Q4 2024.”
“I am pleased to present our results for the third quarter. Revenue for the quarter was $36.2 million, up $7.5 million or 26% as compared to 2024. Total revenue for the quarter is composed of $32.8 million of screening revenue and $3.4 million of development service revenue.”
Start not stated–present
Last confirmed April 28, 2026
GRAL
Diagnostics & Research · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GRAIL, Inc. (GRAL) | Chief Financial Officer | $560,000 | $3,131,535 |
| 2024 | GRAIL, Inc. (GRAL) | Chief Financial Officer | $560,000 | $3,692,821 |
| 2023 | GRAIL, Inc. (GRAL) | Chief Financial Officer | $556,154 | $3,601,324 |